Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I predict we break through .34 by Wednesday, run up to .35 thursday, then through and back to .349 friday afternoon. Followed by PR next wednesday sending the stock to .40 pending any News at ASCO.
You mean from QB to QX designation?
i believe we will see more buying coming in as we get closer to june 2nd. I also believe we will get through .35 and approach .40. I agree we need news AND volume to continue the uptrend and LP knows this too. And while LP hasn't been as concerned with PPS and more focused on big picture end game, she certainly knows we need to get to higher levels to get warrant money in.
We don't know what he said or what he meant, which is why several posters have been asking for clarification. It could mean that they have been submitted and we are in review and hoping for approval to announce at ASCO.
Can you share what, exactly, in your conversation makes you feel positive? I know he cannot share info, dates, etc....so are you relying on his general demeanor or something more?
Makes sense. Concern is that we are up against the authorized share limit soon, not much room for issuing shares with all warrants outstanding. This is another reason I believe LP knows she needs to get results out asap. Positive topline, PPS move up, warrant conversion for cash gets us through the rest of the year without a raise. And, possibly an uplist and no R/S. IMO.
Flipper do you believe this increase recently has to do with warrant conversion? Not sure there is another explanation without capital raise and PR on it.
False Alarm but strange indeed. I would take back all of my negativity towards LP's strategy if she jumps the shark and releases a Topline PR prior to ASCO.....
Very Strange. I think it was eleven minutes without a trade and then a bump up. Hmmm.
Is it halted?
Strange, no trades in the first 5 minutes?
I believe we will get a substantial update at ASCO. If not topline, we could get several data items that confirm the direction and efficacy if sustained through unblinding. Number alive, maybe a refresh from final collection but short of topline? Possibly information on SAP submissions and/or approval. Either way I do not believe that LP would present anything if it was not positive and significant. If she simply gives a repeat of SNO or no new information she wouldn't be going. I happen to be one of those who believe the unblinded, separated data will be even more impressive.
Seems to me the attitude on this board has shifted over the past few weeks to a non-event expectation from ASCO. And, kicking the can down the road to late summer or SNO again. I still believe we get valuable insight and information. What that is I do not know and contrary to the conventional wisdom, I don't think LP will wait for another conference to release topline or unblind. It will be as soon as humanly possible. She knows the burn rate, she knows we the PPS get hammered. She is looking for the end game and isn't as concerned with current share price, I get it. However, she knows that if she doesn't release info to support the PPS, it will be almost impossible to raise additional money this summer.
Sorry, that's a legitimate estimate for topline, undlinded data. If all data bears out and approvals from FDA and others, sure, it could be worth tens of billions. But that time, unfortunately, is a ways away. I hope I'm wrong.
I certainly don't think we go to $10+ dollars as some have predicted. However, unequivocal, positive results will move the stock, IMO. My guess is up to $2 or so. Fully diluted value of around $2 billion is in line with a prospective new treatment or drug prior to FDA approval after positive topline. The real money wouldn't come until after FDA approval or buyout.
I doubt we get topline, but, positive topline numbers remove LP from the conversation, so to speak. The numbers will speak for themselves. I still believe the SAP approvals and "pioneering" that had to go into them would be a positive in that an approval means the FDA is on board with how the numbers will be looked at. I imagine biotechs craft the the final SAP to put the best foot forward for trial success based on what they know before unblinding.
What, in your opinion can they discuss, PR, announce (other than topline) that would keep the share price moving up, or jump to new highs?
1. I doubt LP will give a timeline
2. SAP status? All 4 filed and approved?
3. Final data collected and being compiled/analyzed?
4. Other?
looks like light selling pressure as we broke the recent uptrend chart-wise. Support at .30 on 50-day MA. Hopefully we don't get there. Decent support bid of 170,000 shares and stalled selling.
CEO salaries are usually based on performance and results. SO, based on her performance (whether you think it is good, bad or indifferent) she would likely not be CEO any longer without the share control she has. All decisions roll up to her. I personally do not believe we would be where we are with a different game plan. The only thing worse than the plummeting share price, subsequent delisting, toxic financings and a silence strategy that ensued is bankruptcy. Again, based on performance I think she fails. It is likely, based on where we are, the opposite decision across the board over the past three years would arguably have us in a better place...since we cannot get much worse. I believe we will succeed in spite of all this, JMHO.
It appears to me that selling pressure ramped up over the past hour but the bid at .33 seems to be holding. We shall see.
That would be nice too!
No. More like: "after months of amending and submitting our SAP, the FDA has approved our final data analysis plans. Concurrently we have collected and are scrubbing final data for topline release."
Agreed, Agreed, Agreed. If not topline, SAP status/approval is a minimum. They have been at this for over six months. Something has to be completed and disclosed.
It seems the majority of posters believe ASCO will bring something new, big, exciting....however you describe it. I do not hear many thinking that topline will be released. I just hope it is enough to keep the upward stock trend so warrant money starts to flow in.
Not sure who posted it earlier but short interest avtually grew slightly for the 4/30 reporting.
Symbol NWBO
04/30/2019
NORTHWEST BIOTHERAPEUTICS INC
NWBO
Other OTC
12,645,469 current
12,588,783 previous
56,686. Change
I don't think the start of another trial would be big news. They have been talking for a long time about two trials that haven't started yet. NWBO does not have the money to start another trial AND finish the phase 3 trial. So, if someone like BMY is so confident that they agree to pay for the whole trial and announce the start of it, I guess that would be decent news. The only thing, IMO, that gets the stock over $1, brings in warrant money and gets the other trials started is topline release, period.
I believe the final revised versions submitted for trial end is important. Especially if the FDA agrees with the way NWBO wants to present the data.
Agreed. I supposed it is possible. However, we will be about 6 months from last update by LL at SNO. So, will they just give sneak peek into what they have seen since then, data-wise? Is that even worth it vs. topline release? I believe they have the data and have not shared it. It shouldn't take 6 months to collect the data from the remaining sites.
Maybe that all SAP's filed and being reviewed? These only needed revision "A SAP also is prespecified before the start of a trial. It may be amended during the trial while the data are blinded but is finalized before the analysis is completed and the data are unblinded." NWBO has likely been working on revisions since ASCO18.
To me, if it is announced that all 4 SAP's have been submitted and approved, we have our first home run. Meaning that if regulators accept the amendments for reviewing data, we have probably addressed and convinced them that pseudo progression issues need to be readjudicated in our favor.
No matter what we need something at ASCO!!!
Semantics again. They HAVE been completing these processes since last year. I have no idea how far along they are. There were 80+ trial sites but I don't believe they have to go to all of them. It is my understanding that when the last patient treated at a site passes, they have final data from there, done. Still, the only delay on collecting data is if there are questions or missing data which needs answers. The SAP's should have been close to completion last year. Submission, review, edits, approval...who knows how long that takes. If LP would tell us when they were submitted, we could get an idea.
10-Q didn't have anything earth-shattering but I don't like the cash position. As I have thought, burn rate will increase and by third quarter we will be broke again without warrant money. Otherwise it will be dilution. So, this points to LP Announcing results in time to get the PPS high enough for warrant money to flow in. We also do not have any money to star a new trial.
What bothered me most this week is the response a poster here received from David Innes. Sounded to me like he was plainly saying we are not planning on delivering data results at ASCO.
NITE is notorious for trading shenanigans. Whether they are doing this themselves, truly making a market or legitimately trading for someone. I don't know. We will never find out. What we will see is who stays and who goes when volume gets over 10 million shares a day at $.50-1.00 or higher and real money is at stake.
most of my position (530K) is a few years old unfortunately. But I have doubled up with another 250,000 shares in the past two months or so thinking we would get something/anything by June. Probably have to pull some back from my original shares and let the rest ride risking higher reentry. But, with no news it may be lower reentry.
Agreed. And if that is the case, I will be taking chips off the table until Fall. Might be a risk but I don't see news shortly after ASCO if it is not at ASCO. I have not traded this stock but probably will to take advantage of other opportunities until there is news.
Maybe less. I believe the anticipation of something very positive at ASCO will start next week off with buying again and if we break through .35 I think it will run for the week.
sorry, 2:20 was the 400 share print
I am going to keep playing along. On the one minute chart, at 1:40 there was a lone print for 200 shares = I need Shares badly but do not take the stock down. then at 2:40, there was a lone 400 share trade = Keep trading it sideways. BTW, all the other 1 minute slots have more shares traded.
Doesn't seem possible in a legitimate market for almost three days of trading and almost 4 million shares traded to stay in a range like this.
Continue??? He's on the wrong path then. Haven't heard one thing from the company since he started.
And, Let's not let shareholder value or material information dissemination get in the way either. If there is nothing substantial at or before ASCO we drop big time, IMO. That's what they have been hiding behind. SAP submission, approval, data lock, any and all of these are routinely PR'd by biotech companies. NWBO chooses not to or they haven't done any of these things.
I've heard the word "coiled" used recently. That's what I believe. This NOT normal market action. The stock would move back and forth above .34 until supply/demand even out and it picks a direction. This tight two-day range of a .05 is orchestrated, IMO. The next buying wave blows through .34 and I am not sure .40 will stop it.